

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Applicant:** Xiao et al.**Group Art Unit:** Not yet assigned**Serial No.:** Not yet assigned

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail (Label No. EV193718372US) in an envelope addressed to: Commissioner for Patents, Alexandria, VA 22313-1450 on:

Filed: Herewith**For:** Methods and Compositions
for The Treatment of Cancer

Date of Deposit:


Person making Deposit:

Signature:

Date of Signature:

6/23/2003

BONNIE FERGUSON



6/23/2003

Examiner: Not yet assigned**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:


Applicant herewith submits forms PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR §§ 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentability of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

As this Information Disclosure Statement is being submitted prior to three months after the filing date of this Application, no fee or certification is thought to be required, pursuant to 37 CFR §1.97(b). If Applicant is in error in this regard, please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted,

Date: 06/23/03



Carlos A. Fisher
Reg. No. 36,510
ALLERGAN, INC.
T2-7H
2525 Dupont Drive
Irvine, CA 92612
Tel: 714-246-4920
Fax: 714-246-4249

LIST OF REFERENCES CITED BY APPLICANT

ATTY. DOCKET: 17512(HL)	SERIAL NO.: Not Assigned
APPLICANT: Xiao et al	TITLE: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
FILING DATE: Submitted herewith	GROUP: Not assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

AA	✓	Chung, "The Genetic Basis of Colorectal Cancer: Insights Into Critical Pathways of Tumorigenesis", Gastroenterology 119:854-865(2000)
AB	✓	Harada et al, "Intestinal polyposis in mice with a dominant stable mutation of the β -catenin gene", The EMBO J. 18 No. 21: pp. 5931-5942(1999)
AC	✓	Easwaran et al, "Cross-regulation of β -catenin-LEF/TCF and retinoid signaling pathway", Current Biology Vol. 9 No. 23: 1415-1418 (1999)
AD	✓	Kopf et al, "Dimerization with Retinoid X Receptors and Phosphorylation Modulate the Retinoic Acid-induced Degradation of Retinoic Acid Receptors α and γ through the Ubiquitin-Proteasome Pathway", J. Biol. Chem. 275: 33280-33288 (2000)
AE	✓	Adachi et al, "Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma", Hepatology 35: 332-340 (2002)
AF	✓	Nagpal et al, "Retinoid-dependent Recruitment of a Histone H1 Displacement Activity by Retinoic Acid Receptor", J. Biol. Chem. 274:22563-22568 (1999)
AG	✓	Klein et al, "Recruitment of Nuclear Receptor Corepressor and Coactivator to the Retinoic Acid Receptor by Retinoid Ligands", J. Biol. Chem. 275:19401-19408 (2000)
AH		de Wet et al, "Firefly luciferase gene: structure and expression in mammalian cells", Mol. Cell. Biol. 7, 725-737 (1987)

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.